Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | STK012 |
| Synonyms | |
| Therapy Description |
STK012 is a PEGylated IL-2 mutein selective to CD25 and CD122, which potentially leads to increased anti-tumor immune response (Cancer Res 2021;81(13_Suppl):Abstract nr 1744). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STK012 | STK 012|STK-012 | STK012 is a PEGylated IL-2 mutein selective to CD25 and CD122, which potentially leads to increased anti-tumor immune response (Cancer Res 2021;81(13_Suppl):Abstract nr 1744). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05098132 | Phase I | Carboplatin + Pembrolizumab + Pemetrexed Disodium STK012 Pembrolizumab + STK012 Carboplatin + Pembrolizumab + Pemetrexed Disodium + STK012 | Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (SYNERGY-101) | Recruiting | USA | 0 |